Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Lytnup
Lytnup Mar. 13 at 5:25 PM
$MDNAF - Secure FDA guidance on first potential registrational trial of MDNA11 in at least one advancer cancer indication in 2L/3L setting post-ICI therapy, including dose selection for Project Optimus - File an investigational new drug (IND) application for MDNA113 in H2 2026 and initiate a Phase 1/2a trial by Q4 2026 Strengthen the balance sheet through partnership and/or financing by mid-2026 in preparation for registrational trial for MDNA11 and commence FIH trial for MDNA113 - Present new pre-clinical and clinical data on bizaxofusp and IL-4Ralpha biology in recurrent GBM in Q1, 2026 Advance and close a strategic collaboration or partnership for bizaxofusp in 2026 - Strengthen management team and board of directors throughout 2026 GLTA -
2 · Reply
Lytnup
Lytnup Mar. 13 at 5:24 PM
$MDNAF It’s hard to know who is selling, or why there is such a lack of support for a company who continues to present best in class data. As a long term shareholder, it’s equally hard to watch. Unfortunately, there simply isn’t much to do but wait for Dr. Merchant to find a suitor / partner, or raise more money to pursue their latest goals for 2026: - Complete patient enrollment in ABILITY-1 study in MDNA11 monotherapy and combination arms across prioritized indications ( cutaneous melanoma, endometrial cancer, MSI-H/dMMR and MSS/TMB-H cancers) including any new expansion cohorts (for eg, CRC and NSCLC) with a focus on 2L/3L in post–anti-PD1 settings - Report updated clinical data from MDNA11 monotherapy and combination expansion cohorts including 2L/3L and last-line anti-PD1–treated patients enrolled within the ABILITY-1 study - Share interim clinical data from the Phase 1/2 study of MDNA11 in neoadjuvant melanoma trial (NEO-CYT) throughout 2026
1 · Reply
boomshiva
boomshiva Mar. 13 at 5:01 PM
$MDNAF 7% on 72 000 shares......smells like someone's bailed.
0 · Reply
Gobblin
Gobblin Mar. 10 at 10:39 PM
$MDNAF Servier Pharmaceuticals’s recent definitive agreement to acquire Day One Biopharmaceuticals is a tremendous milestone for the pediatric brain tumor community. While this transaction is entirely independent of Medicenna Therapeutics Corp., it sends a powerful strategic signal about structural trends in our space: the neuro-oncology sector is heating up
1 · Reply
Gobblin
Gobblin Mar. 10 at 10:35 PM
$MDNAF https://www.linkedin.com/company/medicenna-therapeutics-corp-/
1 · Reply
Biosectors
Biosectors Mar. 10 at 4:45 PM
$MDNAF Next few weeks till end of March and some data read outs in April plus Optimus meeting Update in May hopefully will make this company a worth lot more and market will react positively not like now where big guys are suppressing this to buy this out cheap for its pipeline and 113 platform that’s a revenue puller with patents till 2040. Good luck longs
2 · Reply
Gobblin
Gobblin Mar. 7 at 11:47 PM
$MDNAF - slow and steady win the race
3 · Reply
Lytnup
Lytnup Mar. 5 at 11:07 PM
$MDNAF While we wait for the next catalyst, David has posted several articles that (I think) are focused on the expanding role that MDNA11 plays in repairing the entire immunological system, rather than merely treating the cancerous symptoms. I only wish I could easily interpret the essays (sigh) https://open.substack.com/pub/davidbakke/p/operational-playbook-v3?r=10wt7d&utm_medium=ios https://substack.com/@david132748/note/p-189365271?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
2 · Reply
Biosectors
Biosectors Feb. 26 at 3:58 PM
$MDNAF Good morning all Longs Watch the bid war on Monday and have fun Our patience and prayers are about to be answered in kind in the next 4 weeks or so This is a minimum 20$ is my guess hope and prayer for holding since 2022 and 🤞 now Good luck all
6 · Reply
Dipper2013
Dipper2013 Feb. 25 at 8:01 PM
$MDNAF
0 · Reply
Latest News on MDNAF
No data available.
Lytnup
Lytnup Mar. 13 at 5:25 PM
$MDNAF - Secure FDA guidance on first potential registrational trial of MDNA11 in at least one advancer cancer indication in 2L/3L setting post-ICI therapy, including dose selection for Project Optimus - File an investigational new drug (IND) application for MDNA113 in H2 2026 and initiate a Phase 1/2a trial by Q4 2026 Strengthen the balance sheet through partnership and/or financing by mid-2026 in preparation for registrational trial for MDNA11 and commence FIH trial for MDNA113 - Present new pre-clinical and clinical data on bizaxofusp and IL-4Ralpha biology in recurrent GBM in Q1, 2026 Advance and close a strategic collaboration or partnership for bizaxofusp in 2026 - Strengthen management team and board of directors throughout 2026 GLTA -
2 · Reply
Lytnup
Lytnup Mar. 13 at 5:24 PM
$MDNAF It’s hard to know who is selling, or why there is such a lack of support for a company who continues to present best in class data. As a long term shareholder, it’s equally hard to watch. Unfortunately, there simply isn’t much to do but wait for Dr. Merchant to find a suitor / partner, or raise more money to pursue their latest goals for 2026: - Complete patient enrollment in ABILITY-1 study in MDNA11 monotherapy and combination arms across prioritized indications ( cutaneous melanoma, endometrial cancer, MSI-H/dMMR and MSS/TMB-H cancers) including any new expansion cohorts (for eg, CRC and NSCLC) with a focus on 2L/3L in post–anti-PD1 settings - Report updated clinical data from MDNA11 monotherapy and combination expansion cohorts including 2L/3L and last-line anti-PD1–treated patients enrolled within the ABILITY-1 study - Share interim clinical data from the Phase 1/2 study of MDNA11 in neoadjuvant melanoma trial (NEO-CYT) throughout 2026
1 · Reply
boomshiva
boomshiva Mar. 13 at 5:01 PM
$MDNAF 7% on 72 000 shares......smells like someone's bailed.
0 · Reply
Gobblin
Gobblin Mar. 10 at 10:39 PM
$MDNAF Servier Pharmaceuticals’s recent definitive agreement to acquire Day One Biopharmaceuticals is a tremendous milestone for the pediatric brain tumor community. While this transaction is entirely independent of Medicenna Therapeutics Corp., it sends a powerful strategic signal about structural trends in our space: the neuro-oncology sector is heating up
1 · Reply
Gobblin
Gobblin Mar. 10 at 10:35 PM
$MDNAF https://www.linkedin.com/company/medicenna-therapeutics-corp-/
1 · Reply
Biosectors
Biosectors Mar. 10 at 4:45 PM
$MDNAF Next few weeks till end of March and some data read outs in April plus Optimus meeting Update in May hopefully will make this company a worth lot more and market will react positively not like now where big guys are suppressing this to buy this out cheap for its pipeline and 113 platform that’s a revenue puller with patents till 2040. Good luck longs
2 · Reply
Gobblin
Gobblin Mar. 7 at 11:47 PM
$MDNAF - slow and steady win the race
3 · Reply
Lytnup
Lytnup Mar. 5 at 11:07 PM
$MDNAF While we wait for the next catalyst, David has posted several articles that (I think) are focused on the expanding role that MDNA11 plays in repairing the entire immunological system, rather than merely treating the cancerous symptoms. I only wish I could easily interpret the essays (sigh) https://open.substack.com/pub/davidbakke/p/operational-playbook-v3?r=10wt7d&utm_medium=ios https://substack.com/@david132748/note/p-189365271?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
2 · Reply
Biosectors
Biosectors Feb. 26 at 3:58 PM
$MDNAF Good morning all Longs Watch the bid war on Monday and have fun Our patience and prayers are about to be answered in kind in the next 4 weeks or so This is a minimum 20$ is my guess hope and prayer for holding since 2022 and 🤞 now Good luck all
6 · Reply
Dipper2013
Dipper2013 Feb. 25 at 8:01 PM
$MDNAF
0 · Reply
Biosectors
Biosectors Feb. 22 at 2:13 PM
$MDNAF Good morning all longs This is the one and only one long standing best in class IL in market and all big guys have failed sending billions and back to the grind. This is a cash cow for big pharma till 2040 with patents protected across 11,55 and 113 platform. I am holding this for a bid war soon and my estimate is around 25$ plus for the potential since there is no competition at all it’s a scarcity premium company every big pharma wants to progress their onco franchise. Good luck all I am cautiously confident and also praying my holdings since 2022 will pay $$ soon in the next few months. Have a nice Sunday and week ahead , let’s goooo MDNAF it’s about time with all good results and ducks lined
2 · Reply
Gobblin
Gobblin Feb. 20 at 8:42 PM
$MDNAF - this slide alone says a lot about future potential…. Check out the quote bottom left corner….
1 · Reply
Dipper2013
Dipper2013 Feb. 20 at 8:09 PM
$MDNAF ..checking..still under a buck..wow..
0 · Reply
Gobblin
Gobblin Feb. 20 at 7:33 PM
$MDNAF https://ir.medicenna.com/static-files/7e0b406a-a060-4bc5-88c4-64234c2f46c2
0 · Reply
Lytnup
Lytnup Feb. 20 at 3:41 PM
$MDNAF Hope everyone has a fabulous weekend; I am done bid-sitting for now (continuing to DCA as funds allow), and am off to prune the fruit trees. Would be great if Dr. Merchant finally finds a partner for his pipeline; looks like he’ll be busy with conferences over the next month or two.
0 · Reply
theoptionsplug
theoptionsplug Feb. 20 at 7:08 AM
THINGS TO WATCH, 2/20/26 👁️ $LAMR $AU $QCOM $MDNAF $SPY
3 · Reply
Lytnup
Lytnup Feb. 19 at 11:42 PM
$MDNAF Medicenna’s IR team has definitely upped their placement strategy. Hopefully it gets noticed. https://www.linkedin.com/posts/medicenna-therapeutics-corp-_science-primer-bizaxofusp-in-deadliest-brain-activity-7430066191622361089-qwDn?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsnC8EBAcKQyUEEvVrkPzTEpnlOSa2bgnk
2 · Reply
Gobblin
Gobblin Feb. 19 at 9:36 PM
$MDNAF
0 · Reply
Gobblin
Gobblin Feb. 18 at 11:27 PM
$MDNAF - Feb 19
1 · Reply
Gobblin
Gobblin Feb. 18 at 9:41 PM
$MDNAF - partnership meetings . Hmmm….
0 · Reply
Dipper2013
Dipper2013 Feb. 18 at 1:57 PM
$MDNAF
0 · Reply
Lytnup
Lytnup Feb. 18 at 1:17 PM
$MDNAF Anybody else having a hard time seeing PRs on the company’s website? https://ir.medicenna.com/node/10361/pdf
0 · Reply